Open Nav

Incysus Therapeutics, Inc.

Introduce company and unique approach to cancer treatments

  • Date:Thursday, October 18
  • Time:10:15 AM - 10:30 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Incysus is focused on developing novel off-the-shelf therapies for cancer, with a particular focus on solid tumor cancers. By using modified gamma delta T cells, our technology addresses the challenges that immunotherapies face targeting cold, low-mutation cancers. Its immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since our founding in 2016, we have filed two INDs and initiated several cancer programs that are in early pre-clinical stages. We expect to begin Phase I trials in its two lead programs-the first for patients with leukemia and lymphoma undergoing stem cell transplantation, and the second in patients with newly diagnosed glioblastoma around year-end.
  • Company
  • Company HQ City:New York
  • Company HQ Country:United States
  • Company HQ State:New York                    
  • CEO/Top Company Official:William Ho
  • Year Founded:2016
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :modifed gamma delta t cells in treatment of glioblastoma
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :Two
  • Previous and Current Investors:Bios Partners
  • Size of Last Investment Round:Series A to date is 8.4 million; third tranche ongoing
  • Total Amount Raised to Date, In All Rounds:$8.4 million